Publication | Open Access

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts

Hematological MalignancyThrombosisLong-term UtilizationBone Marrow FailureBlood TransfusionRing SideroblastsMalignant Blood DisorderImmunologyHematologyPathologyLower-risk Myelodysplastic SyndromesMedicineMyelopoiesis